Rm-2 ga-68 clinical trials
Also written BAY 86-7548 and 68Ga-RM2.
How each study uses rm-2 ga-68 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the rm-2 ga-68 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2015 (3)
| Year | Studies |
|---|---|
| 2015 | 3 |
| 2017 | 1 |
| 2019 | 3 |
| 2020 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 9
Andrei Iagaru (6) · IRCCS San Raffaele (2) · Stanford University (1) · Life Molecular Imaging SA (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Radiopharmaceuticals source
Studies
Open first, then newest update. How each study uses rm-2 ga-68 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- PET/MRI to Stage Prostate Cancer PatientsRecruitingPhase 2IRCCS San RaffaeleNCT06484361Written as 68Ga-RM2How we know
- HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate CancerTerminatedPhase 2Andrei IagaruNCT04264208Written as 68-Ga RM2.How we know
- 68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU TherapyCompletedPhase 1/2Andrei IagaruNCT03949517Written as 68-Ga RM2How we know
- 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate CancerCompletedPhase 2Andrei IagaruNCT03809078Written as 68Ga RM2How we know
- 68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast CancerCompletedPhase 1/2Andrei IagaruNCT03831711Written as Gallium Ga 68-labeled GRPR Antagonist BAY86-7548How we know
- 68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate CancerCompletedPhase 2Andrei IagaruNCT03113617Written as Gallium Ga 68-labeled GRPR Antagonist BAY86-7548How we know
- 68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate CancerCompletedPhase 2/3Andrei IagaruNCT02624518Written as 68Ga-RM2How we know
- PET/MR for Prostate Cancer Restaging: a Phase II Prospective Monocentric StudyCompletedPhase 2IRCCS San RaffaeleNCT05806853Written as 68Ga-RM2How we know
- 68Ga-DOTA-Bombesin PET/MRI in Imaging Patients With Prostate CancerCompletedPhase 2Stanford UniversityNCT02440308Written as 68Ga-DOTA-BombesinHow we know
- PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate CancerTerminatedPhase 1/2Life Molecular Imaging SANCT02483884Written as [68Ga]RM2How we know
As the comparator · 1 — what is tested is compared with rm-2 ga-68
Codes
What other systems call rm-2 ga-68 · ClinicalTrials.gg INT006321
- UNII (FDA) NPI2H5M36DRM-2 GA-68One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | NPI2H5M36D | RM-2 GA-68 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.